Chronic Cannabidiol Administration Mitigates Excessive Daytime Sleepiness and Fatigue in Patients with Primary Hypertension: Insights from a Randomized Crossover Trial.

The chronic effects of cannabidiol (CBD) supplementation on factors that could impact the quality of life (anxiety, sleeping quality, memory, etc.) are poorly explored. Hence, the aim of this study was to establish whether chronic CBD supplementation will improve self-reported outcomes related to quality of life. In this randomized crossover trial, 64 patients with primary hypertension were assigned to receive CBD (225-450 mg) for 5 weeks followed by 5 weeks of placebo or vice versa, with a 2-week washout in-between the two. Self-reported outcomes were assessed using short form-36 (SF-36), Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale (ESS), memory complaint questionnaire (MAC-Q), and state-trait anxiety inventory (STAI). Five-week administration of CBD, but not of placebo, resulted in improvement of ESS score (F = 6.738, = 0.011), as well as fatigue/vitality (Δ = 5.0, < 0.001) and psychological well-being dimensions of SF-36 (Δ = 7.4, = 0.039). No overall benefit of CBD on quality of life was noted ( = 0.674). No changes were seen in total scores of MAC-Q, PSQI, or STAI ( = 0.151, = 0.862, = 0.702, respectively). No significant correlations were found between plasma CBD concentrations and any of the scores. Chronic CBD administration reduced excessive daytime sleepiness, despite the fact that no change was observed in self-reported quality of sleep. Furthermore, self-reported fatigue and psychological well-being dimensions of quality of life also improved following chronic CBD use.